It is important to expand clinical trial access for patients with kidney cancer in order to ensure a representative study population.
Dr. Eric Jonasch
Advertisement
Articles by Dr. Eric Jonasch
The HIF-2a Inhibitor induced clinical responses among patients with von Hippel-Lindau disease–associated kidney cancer, according to results presented at the 2020 ASCO Virtual Scientific Program.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CURE
1
Top 5 Takeaways From ASCO 2026 That Patients Should Know
2
Pumitamig Shows 70% Response in Advanced Lung Cancer Regardless of PD-L1 Status
3
Nurse-Led Quality Initiative Reduces CLABSI Risk in Hematologic Cancer Care
4
A Cancer Survivor Reflects on Organ Donation
5